|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: IL32 |
Gene summary for IL32 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | IL32 | Gene ID | 9235 |
| Gene name | interleukin 32 | |
| Gene Alias | IL-32alpha | |
| Cytomap | 16p13.3 | |
| Gene Type | protein-coding | GO ID | GO:0002376 | UniProtAcc | P24001 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9235 | IL32 | GSM4909281 | Human | Breast | IDC | 5.08e-11 | -5.18e-01 | 0.21 |
| 9235 | IL32 | GSM4909285 | Human | Breast | IDC | 3.59e-27 | -6.87e-01 | 0.21 |
| 9235 | IL32 | GSM4909286 | Human | Breast | IDC | 1.02e-12 | -4.95e-01 | 0.1081 |
| 9235 | IL32 | GSM4909287 | Human | Breast | IDC | 4.93e-02 | 3.07e-01 | 0.2057 |
| 9235 | IL32 | GSM4909289 | Human | Breast | IDC | 4.33e-03 | -6.21e-01 | 0.1064 |
| 9235 | IL32 | GSM4909290 | Human | Breast | IDC | 2.99e-14 | -6.13e-01 | 0.2096 |
| 9235 | IL32 | GSM4909291 | Human | Breast | IDC | 1.09e-11 | -6.15e-01 | 0.1753 |
| 9235 | IL32 | GSM4909293 | Human | Breast | IDC | 1.01e-15 | -6.01e-01 | 0.1581 |
| 9235 | IL32 | GSM4909294 | Human | Breast | IDC | 1.05e-17 | -5.98e-01 | 0.2022 |
| 9235 | IL32 | GSM4909296 | Human | Breast | IDC | 1.61e-22 | -5.92e-01 | 0.1524 |
| 9235 | IL32 | GSM4909297 | Human | Breast | IDC | 2.68e-19 | -5.81e-01 | 0.1517 |
| 9235 | IL32 | GSM4909298 | Human | Breast | IDC | 3.66e-16 | -6.07e-01 | 0.1551 |
| 9235 | IL32 | GSM4909299 | Human | Breast | IDC | 4.55e-08 | -5.00e-01 | 0.035 |
| 9235 | IL32 | GSM4909300 | Human | Breast | IDC | 7.15e-05 | -5.38e-01 | 0.0334 |
| 9235 | IL32 | GSM4909301 | Human | Breast | IDC | 3.48e-22 | -6.32e-01 | 0.1577 |
| 9235 | IL32 | GSM4909302 | Human | Breast | IDC | 2.24e-05 | -4.04e-01 | 0.1545 |
| 9235 | IL32 | GSM4909304 | Human | Breast | IDC | 6.18e-20 | -6.51e-01 | 0.1636 |
| 9235 | IL32 | GSM4909306 | Human | Breast | IDC | 8.98e-10 | -5.00e-01 | 0.1564 |
| 9235 | IL32 | GSM4909307 | Human | Breast | IDC | 2.11e-26 | -6.75e-01 | 0.1569 |
| 9235 | IL32 | GSM4909308 | Human | Breast | IDC | 1.81e-17 | -6.11e-01 | 0.158 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| IL32 | insertion | Frame_Shift_Ins | novel | c.688_689insTGGGTGAAGGAGAAGGTGGTGG | p.Pro230LeufsTer56 | p.P230Lfs*56 | P24001 | protein_coding | TCGA-A8-A07Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unspecific | Exemestane | SD | ||
| IL32 | insertion | In_Frame_Ins | novel | c.691_692insTGGTCC | p.Pro230_Gln231insLeuVal | p.P230_Q231insLV | P24001 | protein_coding | TCGA-A8-A07Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unspecific | Exemestane | SD | ||
| IL32 | SNV | Missense_Mutation | novel | c.638N>A | p.Gly213Glu | p.G213E | P24001 | protein_coding | tolerated_low_confidence(0.39) | probably_damaging(0.948) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| IL32 | SNV | Missense_Mutation | rs371449782 | c.389N>A | p.Gly130Asp | p.G130D | P24001 | protein_coding | tolerated(0.27) | benign(0.18) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
| IL32 | SNV | Missense_Mutation | rs538977484 | c.511N>A | p.Gly171Arg | p.G171R | P24001 | protein_coding | tolerated(0.59) | benign(0) | TCGA-AA-A01T-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | CR |
| IL32 | SNV | Missense_Mutation | c.314N>T | p.Ala105Val | p.A105V | P24001 | protein_coding | tolerated(0.28) | benign(0.001) | TCGA-D5-6537-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | PD | |
| IL32 | SNV | Missense_Mutation | novel | c.490N>T | p.Arg164Trp | p.R164W | P24001 | protein_coding | tolerated(0.06) | possibly_damaging(0.858) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| IL32 | SNV | Missense_Mutation | novel | c.368N>T | p.Arg123Ile | p.R123I | P24001 | protein_coding | deleterious(0.01) | possibly_damaging(0.635) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| IL32 | SNV | Missense_Mutation | novel | c.467N>T | p.Arg156Ile | p.R156I | P24001 | protein_coding | deleterious(0) | probably_damaging(0.961) | TCGA-B5-A1MR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| IL32 | SNV | Missense_Mutation | rs777924344 | c.379N>T | p.Arg127Trp | p.R127W | P24001 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |